Plecanatide vs Roxadustat
Head-to-head comparison of Plecanatide (Plecanatide) and Roxadustat (Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Roxadustat |
|---|---|---|
| Category | Gastrointestinal | Muscle & Performance |
| Full Name | Plecanatide | Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor |
| Molecular Weight | Approx. 1620 Da | 352.35 Da |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | ~12-16 h |
| Amino Acids | 16 | N/A |
| Typical Dose | 3 mg once daily | 70-100 mg orally three times weekly |
| Route | Oral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 180 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Roxadustat Benefits
- ✓induces endogenous EPO
- ✓improves iron handling
- ✓raises hemoglobin
- ✓may improve exercise tolerance
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Roxadustat Dosing
70-100 mg orally 3x weekly|Titrate by hemoglobin response|Monitor iron indices regularly
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Roxadustat Side Effects
- ⚠nausea
- ⚠hypertension
- ⚠thrombotic events
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Roxadustat
Large clinical studies support roxadustat for anemia, especially in chronic kidney disease populations. Direct VO2 max enhancement data in healthy athletes are limited, so its performance effects remain mostly inferential.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.